Which of the following medications is subject to a Risk Evaluation and Mitigation Strategy (REMS) program because current patients should avoid becoming pregnant?

Sertraline is an antidepressant that belongs to the selective serotonin reuptake inhibitors (SSRIs) class. While there are some precautions regarding its use during pregnancy, it does not have a REMS program in place specifically to prevent pregnancy. The risks associated with sertraline are managed through standard prescribing information rather than a specialized risk management strategy.

Ondansetron is an antiemetic commonly used to prevent nausea and vomiting. Although there have been some concerns regarding its use in pregnancy, particularly in the first trimester, it is not classified under a REMS program. The existing guidance for ondansetron does not require the same level of risk mitigation as mycophenolate.

Montelukast is a leukotriene receptor antagonist used primarily for asthma and allergies. There are no specific pregnancy-related risks that warrant a REMS program. While patients are advised to consult their healthcare providers regarding its use during pregnancy, montelukast does not have the same level of concern as mycophenolate regarding potential reproductive harm.